Otava

Otava presents a new Glycogen synthase kinase-3 (GSK3) focused library with 1000 compounds

Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an GSK3 inhibitors have now been shown to be effective in normalizing blood glucose levels in animal models of type 2 diabetes, with their effects seeming to occur primarily through an increase in hepatic glycogen synthesis and a decrease in hepatic gluconeogenesis. GSK3 inhibitors might also have potential for neurodegenerative disorders, such as Alzheimer's disease.

This library has been created as a part of a project aimed at design of a large set of receptor-based sharp-focused libraries. In the framework of this project Otava In-house Stock Collection (100 000 compounds) was used for library preparation.

Design of the focused libraries consists in Lipinsky/Veber rules filtering and flexible docking in a protein target of certain enzyme family. Further computational analysis for the presence of critical receptor-ligand hydrogen bond(s) and docking score refinement makes our focused libraries good starting point for drug discovery purposes.
The detection of H-bonding between ligand and key GSK3 residue (Val135) was used for the library preparation.

About Otava
Otava supplies Receptor Based and Target Focused compound libraries, custom synthesis, fine chemicals, ProHit compounds, protein kinase inhibitors, combinatorial chemistry templates and building blocks, fluorescent cyanine dyes, Noteworthy Compounds. They offer design and development of fluorescent probes, kits and reagents.
Company contact information:

OTAVA
P.O. Box 88
Kyiv 187, 03187
Ukraine
E-mails:
info**et**otavachemicals.com
mailotava**et**gmail.com

OTAVA – North American Division
15 Dundonald St., Suite 1902
Toronto, ON M4Y 1K4
Canada
Tel.: 1-416-305-9979
Fax: 1-866-881-9921 (Toll-free in US & Canada)
E-mail: north.america**et**otavachemicals.com